Table 5 Univariate analysis of survival (n = 41)
From: Brain metastases from hepatocellular carcinoma: clinical features and prognostic factors
| Â | Patients | Mean survival (months) | Median survival (months) | p-Value (log-rank) |
|---|---|---|---|---|
Overall survival | 41 | 4.5 | 3 | Â |
Characteristics | Â | Â | Â | Â |
Gender | Â | Â | Â | 0.386 |
   Male | 33 | 4.7 | 3 |  |
   Female | 8 | 3.6 | 2.5 |  |
Age (years) | Â | Â | Â | Â |
   < 50 | 23 | 4.4 | 3 | 0.893 |
   ≥ 50 | 18 | 4.6 | 3.5 |  |
Primary tumor | Â | Â | Â | 0.156 |
   Controlled | 16 | 5.8 | 3.5 |  |
   Uncontrolled | 25 | 3.7 | 3 |  |
Etiology | Â | Â | Â | Â |
   Hepatitis B | 30 | 4.1 | 3 | 0.308 |
   None | 11 | 5.6 | 3 |  |
Child-Pugh's classification | Â | Â | Â | Â |
   A | 27 | 4.9 | 3.5 | 0.364 |
   B/C | 14 | 3.8 | 3 |  |
APF (ng/ml) | Â | Â | Â | Â |
   < 400 | 15 | 3.4 | 2 | 0.218 |
   ≥ 400 | 26 | 5.1 | 3.5 |  |
CEA (ng/ml) | Â | Â | Â | Â |
   < 5 | 26 | 4.8 | 3 | 0.725 |
   ≥ 5 | 5 | 3.9 | 3 |  |
CA199 (u/ml) | Â | Â | Â | 0.455 |
   < 35 | 22 | 3.9 | 3 |  |
   ≥ 35 | 10 | 5.6 | 3 |  |
Extracranial metastasis | Â | Â | Â | Â |
   Yes | 33 | 5.2 | 3.5 | < 0.0001 |
   No | 8 | 1.4 | 1 |  |
Lung metastasis | Â | Â | Â | Â |
   Yes | 31 | 5.4 | 4 | 0.001 |
   No | 10 | 1.7 | 1.7 |  |
Bone metastasis | Â | Â | Â | Â |
   Yes | 9 | 5.8 | 4 | 0.272 |
   No | 32 | 4.1 | 2.5 |  |
Brain hemorrhage | Â | Â | Â | Â |
   Yes | 19 | 4.1 | 1.5 | 0.495 |
   No | 22 | 4.9 | 3.5 |  |
Interval (months) | Â | Â | Â | Â |
   < 12 | 16 | 3.5 | 3 | 0.272 |
   ≥ 12 | 25 | 5.1 | 3.5 |  |
Number of brain lesions | Â | Â | Â | Â |
   Single | 24 | 4.2 | 3 | 0.572 |
   Multiple | 17 | 4.9 | 3.5 |  |
Location | Â | Â | Â | Â |
   Supratentorial | 29 | 5 | 3 | 0.293 |
   Infratentorial or combinations | 12 | 3.4 | 1.5 |  |
Treatment | Â | Â | Â | Â |
   Surgery or WBRT and/or SRS | 18 | 6.8 | 4.5 | 0.001 |
   Steroid only | 23 | 2.7 | 1.5 |  |
RPA class | Â | Â | Â | Â |
   I or II | 25 | 6.4 | 6 | < 0.0001 |
   III | 16 | 1.6 | 1 |  |